Ankit Mahadevia, Director at Spero Therapeutics, Inc. (SPRO), sold 5,912 shares at $1.35 ($8K) on 2024-08-27, disclosed to the SEC on 2024-08-29.
Open-market sale of $8k SPRO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |
| SPRO | SELL | 2023-02-06 | $22K | — | Filing → |